We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is de... Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital. Show more
CAMBRIDGE, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing...
CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel...
CAMBRIDGE, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.21 | 14.5833333333 | 1.44 | 1.67 | 1.42 | 203024 | 1.52110628 | CS |
4 | -0.05 | -2.94117647059 | 1.7 | 1.75 | 1.37 | 202253 | 1.52518375 | CS |
12 | 0.29 | 21.3235294118 | 1.36 | 1.89 | 1.3509 | 329184 | 1.66367602 | CS |
26 | 0.51 | 44.7368421053 | 1.14 | 1.89 | 1.04 | 252906 | 1.5425181 | CS |
52 | -0.08 | -4.62427745665 | 1.73 | 1.995 | 0.99 | 270741 | 1.51422791 | CS |
156 | -12.35 | -88.2142857143 | 14 | 19.87 | 0.6801 | 962573 | 2.34876532 | CS |
260 | -9.24 | -84.8484848485 | 10.89 | 23.639 | 0.6801 | 641301 | 3.55809419 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions